Literature DB >> 20454983

Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

C Scheller1, G Arendt, T Nolting, C Antke, S Sopper, M Maschke, M Obermann, A Angerer, I W Husstedt, F Meisner, E Neuen-Jacob, H W Müller, P Carey, V Ter Meulen, P Riederer, E Koutsilieri.   

Abstract

Central dopaminergic (DA) systems are affected during human immunodeficiency virus (HIV) infection. So far, it is believed that they degenerate with progression of HIV disease because deterioration of DA systems is evident in advanced stages of infection. In this manuscript we found that (a) DA levels are increased and DA turnover is decreased in CSF of therapy-naïve HIV patients in asymptomatic infection, (b) DA increase does not modulate the availability of DA transporters and D2-receptors, (c) DA correlates inversely with CD4+ numbers in blood. These findings show activation of central DA systems without development of adaptive responses at DA synapses in asymptomatic HIV infection. It is probable that DA deterioration in advanced stages of HIV infection may derive from increased DA availability in early infection, resulting in DA neurotoxicity. Our findings provide a clue to the synergism between DA medication or drugs of abuse and HIV infection to exacerbate and accelerate HIV neuropsychiatric disease, a central issue in the neurobiology of HIV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454983     DOI: 10.1007/s00702-010-0415-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  32 in total

1.  Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs.

Authors:  S Czub; E Koutsilieri; S Sopper; M Czub; C Stahl-Hennig; J G Müller; V Pedersen; W Gsell; J L Heeney; M Gerlach; G Gosztonyi; P Riederer; V ter Meulen
Journal:  Acta Neuropathol       Date:  2001-02       Impact factor: 17.088

2.  Distribution of brain HIV load in AIDS.

Authors:  C A Wiley; V Soontornniyomkij; L Radhakrishnan; E Masliah; J Mellors; S A Hermann; P Dailey; C L Achim
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

Review 3.  Neurotransmission in HIV associated dementia: a short review.

Authors:  E Koutsilieri; V ter Meulen; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

4.  HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells.

Authors:  G Zauli; P Secchiero; L Rodella; D Gibellini; P Mirandola; M Mazzoni; D Milani; D R Dowd; S Capitani; M Vitale
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

5.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains.

Authors:  Adarsh M Kumar; J B Fernandez; Elyse J Singer; Deborah Commins; Drenna Waldrop-Valverde; Raymond L Ownby; Mahendra Kumar
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

6.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

7.  Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection.

Authors:  Negar Khanlou; David J Moore; Gursharan Chana; Mariana Cherner; Deborah Lazzaretto; Sharron Dawes; Igor Grant; Eliezer Masliah; Ian P Everall
Journal:  J Neurovirol       Date:  2009-04       Impact factor: 2.643

8.  Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis.

Authors:  Benjamin B Gelman; Jeffrey A Spencer; Charles E Holzer; Vicki M Soukup
Journal:  J Neuroimmune Pharmacol       Date:  2006-08-08       Impact factor: 4.147

9.  Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV.

Authors:  Mark Obermann; M Küper; O Kastrup; O Yaldizli; S Esser; J Thiermann; E Koutsilieri; G Arendt; H-C Diener; M Maschke
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

Review 10.  Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration.

Authors:  Shaji Theodore; Wayne A Cass; Avindra Nath; William F Maragos
Journal:  Curr HIV Res       Date:  2007-05       Impact factor: 1.581

View more
  35 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

Review 3.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

Review 4.  Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond.

Authors:  Mike Sathekge; Alicia McFarren; Ekaterina Dadachova
Journal:  Nucl Med Commun       Date:  2014-08       Impact factor: 1.690

Review 5.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 6.  The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.

Authors:  Vanessa Chilunda; Tina M Calderon; Pablo Martinez-Aguado; Joan W Berman
Journal:  Brain Res       Date:  2019-08-29       Impact factor: 3.252

7.  Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.

Authors:  Christina J Schier; William D Marks; Jason J Paris; Aaron J Barbour; Virginia D McLane; William F Maragos; A Rory McQuiston; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurosci       Date:  2017-05-04       Impact factor: 6.167

Review 8.  Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; David Shurtleff
Journal:  Mol Neurobiol       Date:  2011-07-01       Impact factor: 5.590

9.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

10.  Alcohol abuse and HIV infection: role of DRD2.

Authors:  Marisela Agudelo; Pradnya Khatavkar; Adriana Yndart; Changwon Yoo; Rhonda Rosenberg; Jessy G Devieux; Robert M Malow; Madhavan Nair
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.